55 related articles for article (PubMed ID: 15571131)
1. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium.
Jalali A; Amirian ES; Bainbridge MN; Armstrong GN; Liu Y; Tsavachidis S; Jhangiani SN; Plon SE; Lau CC; Claus EB; Barnholtz-Sloan JS; Il'yasova D; Schildkraut J; Ali-Osman F; Sadetzki S; Johansen C; Houlston RS; Jenkins RB; Lachance D; Olson SH; Bernstein JL; Merrell RT; Wrensch MR; Davis FG; Lai R; Shete S; Aldape K; Amos CI; Muzny DM; Gibbs RA; Melin BS; Bondy ML
Sci Rep; 2015 Feb; 5():8278. PubMed ID: 25652157
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
McAleenan A; Jones HE; Kernohan A; Robinson T; Schmidt L; Dawson S; Kelly C; Spencer Leal E; Faulkner CL; Palmer A; Wragg C; Jefferies S; Brandner S; Vale L; Higgins JP; Kurian KM
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013387. PubMed ID: 35233774
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity on chromosomes 10q, 9p, 17p and 13q in malays with malignant glioma.
Zainuddin N; Jaafart H; Isa MN; Abdullah JM
Neurol Res; 2004 Jan; 26(1):88-92. PubMed ID: 14977064
[TBL] [Abstract][Full Text] [Related]
5. [Loss of heterozygosity on chromosomes 1 and 19 in primary brain tumors].
Nielsen KV; Rasmussen BB; Balslev E; Poulsen TS; Schønau A; Ejlertsen B
Ugeskr Laeger; 2007 Jan; 169(2):147. PubMed ID: 17240558
[No Abstract] [Full Text] [Related]
6. Molecular characterization of brain tumors.
Boudreau CR; Liau LM
Clin Neurosurg; 2004; 51():81-90. PubMed ID: 15571131
[No Abstract] [Full Text] [Related]
7. [Malignant gliomas. Oncogenic considerations].
Pérez-Ortiz L; Zaldívar-Vaillant T; Tamayo-Suárez JD
Rev Neurol; 2000 Jul 1-15; 31(1):49-52. PubMed ID: 10948584
[TBL] [Abstract][Full Text] [Related]
8. New innovations and developments for glioma treatment.
Croteau D; Mikkelsen T; Rempel SA; Bogler O; Rosenblum M
Clin Neurosurg; 2001; 48():60-81. PubMed ID: 11692657
[No Abstract] [Full Text] [Related]
9. [A puzzle with more pieces?: entering an era with a handful of glioma suppressor genes].
Ueki K
No To Shinkei; 1998 Jun; 50(6):539-46. PubMed ID: 9656249
[No Abstract] [Full Text] [Related]
10. [Towards a molecular classification of gliomas].
Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
